For over a decade, Lilly has been committed to the global fight against multi-drug resistant tuberculosis (MDR-TB). A new report, released last week, shares insights from a core component of the Lilly MDR-TB Partnership: the technology transfer program.
The story began when independent researchers identified two Lilly-manufactured medicines as effective treatments for MDR-TB. Following this discovery, Lilly set up a novel solution to combat the global rise of the disease. We transferred our trademarks, manufacturing technology, and knowledge to manufacturers in the most affected countries, free of charge, in order to create a reliable and sustainable supply of these two medicines. Here’s a look at our lessons learned:
The MDR-TB Technology Transfer program created sustainable access to safe, effective medicines, by moving the technology closer to the people who needed it most. Since its launch in 2003, the MDR-TB Partnership has been working to empower stakeholders at all levels of the health system to be able to care for people living with MDR-TB around the world.
Across the world, the ongoing fight to eradicate tuberculosis has achieved many hopeful advances, but more work remains to be done. As Lilly continues its work through the MDR-TB Partnership, we hope that the technology transfer can stand as a promising example of the power of innovative thinking and collaboration.